Structural modelling and in silico pharmacology of β-carboline alkaloids as potent 5-HT1A receptor antagonists and reuptake inhibitors

被引:29
|
作者
Ayipo, Yusuf Oloruntoyin [1 ,2 ]
Alananzeh, Waleed A. [1 ]
Ahmad, Iqrar [3 ]
Patel, Harun [3 ]
Mordi, Mohd Nizam [1 ]
机构
[1] Univ Sains Malaysia, Ctr Drug Res, George Town 11800, Malaysia
[2] Kwara State Univ, Dept Chem & Ind Chem, Ilorin, Nigeria
[3] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut Chem, Shirpur, Maharashtra, India
来源
关键词
Major depressive disorder; structural modelling; molecular pharmacology; molecular dynamics; drug design; FORCE-FIELD; PROTEIN; DOCKING; RECOGNITION; COVERAGE; ERRORS;
D O I
10.1080/07391102.2022.2104376
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Serotonin (5-HT) antagonists and reuptake inhibitors (SARIs) are atypical antidepressants for managing major depressive disorder. They are oftentimes applied as adjuvants for ameliorating aftereffects of SSRI antidepressants including insomnia and sexual dysfunction. The few available candidates of this class including lorpiprazole and trazodone also display some daunting side effects, making a continuous search for improved alternatives essential. Natural beta-carboline alkaloids (N beta Cs) are interestingly renowned with broad pharmacological spectrum against several neuropsychiatric disorders including depression. However, their potentials as SARIs remain underexplored. In this study, 982 N beta Cs retrieved from the Ambinter-Greenpharma (Amb) database were virtually screened for potent SARI alternatives using computational and biocheminformatics approaches: homology modelling of 5-HT1A receptor, Glide HTVS, SP and XP molecular docking, molecular dynamics (MD) simulation, ADMET and mutagenicity predictions. The homology receptor was validated as a good representative of human 5HT1A receptor using the RCSB structure validation and quality protocols. From the virtual screening against the 5-HT1A receptor, Amb ligands, Amb18709727 and Amb37857532 showed higher binding affinities by XP scores of -8.725 and -7.976 kcal/mol, and MMGBSA of -87.972 and -107.585 kcal/mol respectively compared to lorpiprazole, a reference SARI with XP score and MMGBSA of -6.512 and -62.788 kcal/mol respectively. They maintained ideal contacts with pharmacologically essential amino acid residues implicated in SARI mechanisms and expressed higher stability and compactness than lorpiprazole throughout the trajectories of 100 ns MD simulation. They also displayed interesting ADME, druggability, low toxicity and mutagenicity profiles, ideal for CNS drug prospects, thus, recommended as putative SARI candidates for further study.
引用
收藏
页码:6219 / 6235
页数:17
相关论文
共 50 条
  • [31] Trazodone Acts as a Serotonin (5-HT) Reuptake Inhibitor and 5-HT1A Receptor Agonist on the 5-HT System
    Ghanbari, Ramez
    El Mansari, Mostafa
    Blier, Pierre
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 242S - 242S
  • [32] Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors
    Bueno, Ana B.
    Gilmore, Jeremy
    Boot, John
    Broadmore, Richard
    Cooper, Jane
    Findlay, Jeremy
    Hayhurst, Lorna
    Marcos, Alicia
    Montero, Carlos
    Mitchell, Stephen
    Timms, Graham
    Tomlinson, Rosemarie
    Wallace, Louise
    Walton, Leslie
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (12) : 3344 - 3348
  • [33] RECEPTOR-BINDING PROFILES OF POTENT AND SELECTIVE 5-HT1A RECEPTOR LIGANDS
    TULP, MTM
    MOL, F
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) : 1109 - 1109
  • [34] Synthesis and biological evaluation of novel γ-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists
    Ivachtchenko, Alexandre V.
    Frolov, Eugene B.
    Mitkin, Oleg D.
    Kysil, Volodymyr M.
    Khvat, Alexander V.
    Okun, Ilya M.
    Tkachenko, Sergey E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (12) : 3183 - 3187
  • [35] MEDI 58-Novel 2-(piperazin-1-yl)quinoline analogs as combined selective serotonin reuptake inhibitors and 5-HT1A receptor antagonists
    Zhou, Dahui
    Stack, Gary P.
    Lo, Jennifer
    Failli, Amedeo A.
    Evrard, Deborah A.
    Harrison, Boyd L.
    Hatzenbuhler, Nicole T.
    Croce, Susan
    Yi, Soo
    Tran, Megan
    Boikess, Steve
    Golembieski, Jeannette
    Hornby, Geoffrey
    Lai, Margaret
    Lin, Qian
    Schechter, Lee E.
    Schilling, Adam D.
    Smith, Deborah L.
    Huselton, Christine
    Beyer, Chad
    Andree, Terrance H.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [36] Screening of 5-HT1A receptor antagonists using molecularly imprinted polymers
    O'Connor, Naphtali A.
    Paisner, David A.
    Huryn, Donna
    Shea, Kenneth J.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (06) : 1680 - 1689
  • [37] Synergistic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists
    Trillat, AC
    Malagié, I
    Mathe-Allainmat, M
    Anmella, MC
    Jacquot, C
    Langlois, M
    Gardier, AM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 357 (2-3) : 179 - 184
  • [38] A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties
    Jankowska, Agnieszka
    Satala, Grzegorz
    Swierczek, Artur
    Pociecha, Krzysztof
    Partyka, Anna
    Jastrzebska-Wiesek, Magdalena
    Gluch-Lutwin, Monika
    Bojarski, Andrzej J.
    Wyska, Elzbieta
    Chlon-Rzepa, Grazyna
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (18) : 1497 - 1514
  • [39] Active conformation of some arylpiperazine postsynaptic 5-HT1A receptor antagonists
    Paluchowska, MH
    Bojarski, AJ
    Charakchieva-Minol, S
    Wesolowska, A
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2002, 37 (04) : 273 - 283
  • [40] FURTHER EVIDENCE FOR THE IMPORTANCE OF 5-HT1A AUTORECEPTORS IN THE ACTION OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
    HJORTH, S
    AUERBACH, SB
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 260 (2-3) : 251 - 255